PE20181298A1 - Inhibidores de bromodominio bivalentes y usos de los mismos - Google Patents
Inhibidores de bromodominio bivalentes y usos de los mismosInfo
- Publication number
- PE20181298A1 PE20181298A1 PE2018001006A PE2018001006A PE20181298A1 PE 20181298 A1 PE20181298 A1 PE 20181298A1 PE 2018001006 A PE2018001006 A PE 2018001006A PE 2018001006 A PE2018001006 A PE 2018001006A PE 20181298 A1 PE20181298 A1 PE 20181298A1
- Authority
- PE
- Peru
- Prior art keywords
- bivalent
- inhibitors
- bromodominium
- refers
- heteroalkylene
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259797P | 2015-11-25 | 2015-11-25 | |
| US201562261703P | 2015-12-01 | 2015-12-01 | |
| US201662338968P | 2016-05-19 | 2016-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181298A1 true PE20181298A1 (es) | 2018-08-07 |
Family
ID=58763670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001006A PE20181298A1 (es) | 2015-11-25 | 2016-11-23 | Inhibidores de bromodominio bivalentes y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10913752B2 (enExample) |
| EP (1) | EP3380100A4 (enExample) |
| JP (2) | JP7385356B2 (enExample) |
| KR (1) | KR20180081809A (enExample) |
| CN (2) | CN108472295B (enExample) |
| AU (2) | AU2016361478B2 (enExample) |
| BR (1) | BR112018009798A8 (enExample) |
| CA (1) | CA3003288A1 (enExample) |
| CL (1) | CL2018001404A1 (enExample) |
| CO (1) | CO2018005370A2 (enExample) |
| CR (1) | CR20180336A (enExample) |
| IL (1) | IL258970A (enExample) |
| MX (1) | MX2018006499A (enExample) |
| PE (1) | PE20181298A1 (enExample) |
| PH (1) | PH12018550070A1 (enExample) |
| RU (1) | RU2742035C2 (enExample) |
| SG (2) | SG10201913450PA (enExample) |
| WO (1) | WO2017091673A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CN108347939B (zh) | 2015-11-25 | 2021-09-28 | 吉利德阿波罗公司 | 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物 |
| US20170166582A1 (en) | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| CA3095415A1 (en) * | 2018-03-30 | 2019-10-03 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
| CN120468320A (zh) * | 2018-10-09 | 2025-08-12 | 加利福尼亚大学董事会 | E3连接酶的共价靶向 |
| CN110101705B (zh) * | 2019-05-07 | 2022-01-14 | 河南农业大学 | Bet家族蛋白抑制剂的抗病毒用途 |
| CN114502534A (zh) | 2019-09-30 | 2022-05-13 | 协和麒麟株式会社 | Bet降解剂 |
| PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
| CN113679724B (zh) * | 2020-05-18 | 2023-04-07 | 中国科学院微生物研究所 | 一种流感病毒小分子抑制剂 |
| CN114276333B (zh) * | 2020-09-28 | 2023-05-09 | 中国科学院上海药物研究所 | 二氢喹喔啉类溴结构域二价抑制剂 |
| US20240208898A1 (en) * | 2021-03-25 | 2024-06-27 | Dana-Farber Cancer Institute, Inc. | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents |
| IT202100015467A1 (it) * | 2021-06-14 | 2022-12-14 | Univ Degli Studi Roma Tre | Inibitori delle proteine BET per l’uso nel trattamento della malattia di Niemann–Pick. |
| CN115626949B (zh) * | 2021-07-14 | 2026-04-14 | 南京科默生物医药有限公司 | 一种bet蛋白靶向降解化合物及其制备方法和用途 |
| AU2024400671A1 (en) | 2023-12-15 | 2026-07-16 | Kyowa Kirin Co., Ltd. | Divalent bet decomposition agent and targeting molecule-drug complex |
| CN119100970B (zh) * | 2024-08-30 | 2025-09-30 | 中国药科大学 | 基于热休克蛋白90的二价抑制剂及其制备方法和应用 |
| KR102979758B1 (ko) | 2024-11-27 | 2026-06-19 | 주식회사 베노바이오 | 카르복스아마이드 유도체를 유효성분으로 포함하는 안질환 예방 또는 치료용 주사제 조성물 및 이를 포함하는 안구용 제제 |
| CN119318655B (zh) * | 2024-12-02 | 2025-09-23 | 合肥综合性国家科学中心大健康研究院 | Mps1-IN-1在作为铁死亡抑制剂及制备用于防治铁死亡相关疾病药物中的应用 |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3709898A (en) | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
| US3681343A (en) | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
| US3812259A (en) | 1971-08-09 | 1974-05-21 | Upjohn Co | Animal feed and process |
| CH622019A5 (en) | 1975-10-23 | 1981-03-13 | Upjohn Co | Process for the preparation of aminotriazolobenzodiazepines |
| FR2329668A1 (fr) | 1975-10-27 | 1977-05-27 | Upjohn Co | Procede de preparation d'aminotriazolobenzodiazepines |
| EP0087850A1 (en) | 1982-01-04 | 1983-09-07 | The Upjohn Company | Benzodiazepines for anti-hypertensive use |
| DE3435973A1 (de) | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
| ES2037013T3 (es) | 1986-01-21 | 1993-06-16 | Boehringer Ingelheim Kg | Procedimiento para preparar tieno-1,4-diazepinas. |
| DE3724164A1 (de) | 1986-07-25 | 1988-01-28 | Boehringer Ingelheim Kg | Neue 1,4-benzodiazepine, ihre herstellung und verwendung |
| DE3878833T2 (de) | 1987-05-28 | 1993-06-09 | Yoshitomi Pharmaceutical | Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben. |
| JPH0676326B2 (ja) | 1988-05-24 | 1994-09-28 | 吉富製薬株式会社 | 循環器系疾患治療薬 |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| EP0387613A1 (de) | 1989-03-03 | 1990-09-19 | Boehringer Ingelheim Kg | Neue Thienodiazepine |
| CA2020806A1 (en) | 1989-07-12 | 1991-01-13 | Karl-Heinz Weber | Thienodiazepine derivatives |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4107521A1 (de) | 1991-03-08 | 1992-09-10 | Boehringer Ingelheim Kg | Neue acylaminosubstituierte hetrazepine |
| JP3239364B2 (ja) | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
| WO1994006802A1 (fr) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| WO1994022872A1 (fr) | 1993-03-30 | 1994-10-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine |
| JP3001979U (ja) | 1994-03-14 | 1994-09-06 | 有限会社マルセ木工 | 竿掛け具 |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| CN1168140A (zh) | 1995-01-06 | 1997-12-17 | 弗·哈夫曼-拉罗切有限公司 | 羟甲基咪唑并二氮杂䓬及其酯 |
| CN1101680C (zh) | 1995-09-09 | 2003-02-19 | 弗·哈夫曼-拉罗切有限公司 | 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| PL330635A1 (en) | 1996-06-12 | 1999-05-24 | Japan Tobacco Inc | Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one |
| US5693641A (en) | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
| WO1998011111A1 (en) | 1996-09-13 | 1998-03-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and medicinal uses thereof |
| US6444664B1 (en) | 1997-04-18 | 2002-09-03 | Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) | Method for controlling the plasma level of lipoproteins to treat alzheimeris disease |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
| US7589167B2 (en) | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
| JP4875277B2 (ja) | 2000-06-16 | 2012-02-15 | 田辺三菱製薬株式会社 | 放出ｐＨ域及び／又は速度制御組成物 |
| US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
| US20060142257A1 (en) | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
| US6979682B2 (en) | 2001-02-23 | 2005-12-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast |
| IL159622A0 (en) | 2001-07-20 | 2004-06-01 | Novo Nordisk Healthcare Ag | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| UY27427A1 (es) | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
| US20030216758A1 (en) | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| JP3096299U (ja) | 2003-02-20 | 2003-09-12 | 宇輪工業股▲ふん▼有限公司 | 足踏み式健康器 |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE50307267D1 (de) | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
| AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2006021548A1 (de) | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2007014838A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007076348A2 (en) | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| KR101062583B1 (ko) | 2006-01-17 | 2011-09-06 | 에프. 호프만-라 로슈 아게 | Ｇａｂａ 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-ａ]피리딘 |
| ES2351367T3 (es) | 2006-02-14 | 2011-02-03 | Vertex Pharmaceuticals Incorporated | Dihidrodiazepinas útiles como inhibidores de proteína quinasas. |
| ATE479434T1 (de) | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| US20070218135A1 (en) | 2006-03-14 | 2007-09-20 | Glenmark Pharmaceuticals Limited | Sustained release matrix pharmaceutical composition |
| DE602007008553D1 (de) | 2006-05-03 | 2010-09-30 | Novartis Ag | Verwendung von organischen verbindungen |
| CN101448830A (zh) | 2006-05-19 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 作为抗增殖剂的二氢碟啶化合物 |
| WO2008009909A1 (en) | 2006-07-17 | 2008-01-24 | Astrazeneca Ab | Pteridimones as modulators of polo-like kinase |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| BRPI0718120A2 (pt) | 2006-10-25 | 2013-11-12 | Chroma Therapeutics Ltd | Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| DK2474523T3 (da) | 2006-12-26 | 2020-07-13 | Lantheus Medical Imaging Inc | Ligander til billeddannelse af hjerte-innervation |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| CN101636399B (zh) | 2007-03-22 | 2012-04-18 | 武田药品工业株式会社 | 可用作plk1抑制剂的取代的嘧啶并二氮杂* |
| WO2008137081A1 (en) | 2007-05-02 | 2008-11-13 | The Trustees Of Columbia University In The City Of New York | Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives |
| KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| AU2008287339A1 (en) | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases |
| BRPI0817315A2 (pt) | 2007-09-25 | 2015-03-17 | Takeda Pharmaceutical | Inibidores de quinase do tipo polo |
| CN101878216B (zh) | 2007-09-28 | 2013-07-10 | 西克拉塞尔有限公司 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
| WO2009067547A1 (en) | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
| WO2009112439A1 (en) | 2008-03-10 | 2009-09-17 | Janssen Pharmaceutica Nv | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| US20110098288A1 (en) | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
| FR2928923B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
| WO2009153197A1 (en) | 2008-06-18 | 2009-12-23 | F. Hoffmann-La Roche Ag | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| WO2010015340A1 (en) | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| WO2010032195A1 (en) | 2008-09-16 | 2010-03-25 | Csir | Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors |
| CN102292341B (zh) | 2008-10-30 | 2014-09-10 | 环行医学有限责任公司 | 对apo a有活性的噻吩并三唑并二氮杂*衍生物 |
| AU2009315754B2 (en) | 2008-11-13 | 2013-08-15 | F. Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes |
| EP2379559B1 (en) | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| EP2389379A1 (en) | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| MX2012003484A (es) | 2009-09-25 | 2012-04-20 | Vertex Pharma | Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa. |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AU2010317096B2 (en) | 2009-11-05 | 2015-03-26 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919433D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CA2779355C (en) | 2009-11-05 | 2018-01-16 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US20120329803A1 (en) | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| ES2606958T3 (es) | 2010-05-14 | 2017-03-28 | Dana-Farber Cancer Institute, Inc. | Compuestos de tienotriazolodiazepina para tratar una neoplasia |
| CN103154246B (zh) | 2010-05-14 | 2015-11-25 | 达那-法伯癌症研究所 | 用于治疗白血病的组合物和方法 |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| WO2011143651A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
| EP2585465B1 (en) | 2010-06-22 | 2014-11-12 | GlaxoSmithKline LLC | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| US20120014979A1 (en) | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| KR20130131461A (ko) | 2011-03-07 | 2013-12-03 | 폰다지오네 텔레톤 | Tfeb 변종 및 그의 용도 |
| GB201106799D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| DE102011082013A1 (de) | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013123521A1 (en) | 2012-02-17 | 2013-08-22 | Nexbio, Inc. | Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients |
| US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
| WO2014023696A1 (en) | 2012-08-08 | 2014-02-13 | Novomatic Ag | Method of and system for tracking gaming activity |
| WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| WO2014071247A1 (en) | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors |
| US9609495B2 (en) * | 2012-11-16 | 2017-03-28 | Verizon Patent And Licensing Inc. | Central information management system |
| JP2016504990A (ja) | 2012-12-20 | 2016-02-18 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン |
| US20140254659A1 (en) | 2013-03-11 | 2014-09-11 | Mediatek Inc. | Video coding method using at least evaluated visual quality and related video coding apparatus |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| BR112015022391B1 (pt) * | 2013-03-12 | 2021-12-21 | Abbvie Inc | Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| EP2968565A2 (en) * | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| AU2014323526B2 (en) | 2013-09-19 | 2020-07-23 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| WO2015081284A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| WO2015085925A1 (en) * | 2013-12-10 | 2015-06-18 | Abbvie Inc. | Bromodomain inhibitors |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| KR20160111520A (ko) | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| WO2015129927A1 (en) | 2014-02-26 | 2015-09-03 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| WO2015131113A1 (en) | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| WO2016022970A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| RU2745999C1 (ru) | 2014-12-05 | 2021-04-05 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| RS61803B1 (sr) | 2015-09-09 | 2021-06-30 | Jubilant Biosys Ltd | Triciklični fuzioni piridin-2-on derivati i njihova upotreba kao inhibitora brd4 |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| ES2745284T3 (es) | 2015-09-11 | 2020-02-28 | Boehringer Ingelheim Int | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos |
| US20170145086A1 (en) | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| KR102934754B1 (ko) | 2015-11-25 | 2026-03-04 | 이펙터 테라퓨틱스, 인크. | Eif4a-억제 화합물 및 이에 관련된 방법 |
| US20170166582A1 (en) | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| PL3380479T3 (pl) | 2015-11-25 | 2023-05-08 | Gilead Apollo, Llc | Triazolowe inhibitory acc i ich zastosowania |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CN108347939B (zh) | 2015-11-25 | 2021-09-28 | 吉利德阿波罗公司 | 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物 |
| WO2017094750A1 (ja) | 2015-12-01 | 2017-06-08 | 日本農薬株式会社 | ３ｈ‐ピロロピリジン化合物若しくはそのｎ‐オキサイド、又はそれらの塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| GB201608797D0 (en) | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
-
2016
- 2016-11-23 CR CR20180336A patent/CR20180336A/es unknown
- 2016-11-23 US US15/778,831 patent/US10913752B2/en active Active
- 2016-11-23 EP EP16869229.1A patent/EP3380100A4/en not_active Withdrawn
- 2016-11-23 CN CN201680069075.2A patent/CN108472295B/zh active Active
- 2016-11-23 WO PCT/US2016/063502 patent/WO2017091673A2/en not_active Ceased
- 2016-11-23 KR KR1020187017441A patent/KR20180081809A/ko not_active Withdrawn
- 2016-11-23 JP JP2018526853A patent/JP7385356B2/ja active Active
- 2016-11-23 RU RU2018122641A patent/RU2742035C2/ru active
- 2016-11-23 CN CN202210306276.7A patent/CN114957291A/zh active Pending
- 2016-11-23 MX MX2018006499A patent/MX2018006499A/es unknown
- 2016-11-23 BR BR112018009798A patent/BR112018009798A8/pt not_active IP Right Cessation
- 2016-11-23 CA CA3003288A patent/CA3003288A1/en not_active Abandoned
- 2016-11-23 AU AU2016361478A patent/AU2016361478B2/en not_active Ceased
- 2016-11-23 PE PE2018001006A patent/PE20181298A1/es unknown
- 2016-11-23 SG SG10201913450PA patent/SG10201913450PA/en unknown
- 2016-11-23 SG SG11201803210YA patent/SG11201803210YA/en unknown
-
2018
- 2018-04-26 IL IL258970A patent/IL258970A/en unknown
- 2018-05-23 CO CONC2018/0005370A patent/CO2018005370A2/es unknown
- 2018-05-24 CL CL2018001404A patent/CL2018001404A1/es unknown
- 2018-05-25 PH PH12018550070A patent/PH12018550070A1/en unknown
-
2020
- 2020-12-09 AU AU2020286224A patent/AU2020286224A1/en not_active Abandoned
- 2020-12-15 US US17/122,258 patent/US20220119416A9/en not_active Abandoned
-
2021
- 2021-11-29 JP JP2021193552A patent/JP2022043073A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36371A (es) | Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| MX376433B (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| EA201691579A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| MX373711B (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| BR112017002942A2 (pt) | compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53 | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
| EA201790632A1 (ru) | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса | |
| CO2017000211A2 (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| ECSP18056196A (es) | Derivados de indano |